参考文献
［1］Poorolajal J,Hooshmand E,Mahjub H,et al.Survival rate of AIDS disease and mortality in HIV-infected patients:a Meta-analysis[J].Public Health,2016,139:3-12.
［2］Weber R,Ruppik M,Rickenbach M.Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study[J].HIV Med,2013,14（4）:195-207.
［3］常静，孙琳，吕莉萍.AIDS合并肝细胞癌临床病理分析［J］.肝胆胰外科杂志，2022，6（34）：340-343.
［4］Béguelin C,Moradpour D,Sahli R,et al.Swiss HIV cohort study.Hepatitis deltaassociated mortality in HIV/HBV-coinfected patients[J].J Hepatol,2017,66（2）:297-303.
［5］刘思宇，陈晓红.中国部分地区人类免疫缺陷病毒感染者/艾滋病患者合并感染HBV或/和HCV的研究进展［J］.中国病毒病杂志，2020，10（3）：213-217.
［6］张福杰.我国接受抗病毒治疗的HIV/AIDS患者HBV或HCV合并感染率及合并感染对ART疗效影响［C］//全国第四届中西医结合传染病学术会议论文汇编，中国中西医结合学会传染病专业委员会，2012.
［7］Jensen BE,Oette M,Haes JH,et al.HIV-associated gastrointestinal cancer[J].Oncol Res Treat,2017,40（3）:115-118.
［8］Jindal A,Thadi A,Shailubhai K,2019.Hepatocellular carcinoma:Etiology and current and future drugs[J].J Clin Exp Hepatol,9（2）:221-232.
［9］Kallas E,Huik K,Türk S,2016.T cell distribution in relation to HIV/HBV/HCV coinfections and intravenous drug use[J].Viral Immunol,29（8）:464-470.
［10］Vujkovic-Cvijin I,Dunham RM,Iwai S.Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism[J].Sci Transl Med,2013,5（193）:193ra91.
［11］John R.Goldblum，Laura W Lamps，Jesse K Mc Kenney，et al.罗塞和阿克曼外科病理学［M］.回允中，译.北京：北京大学医学出版社，2021.
［12］Ringelhan M,Pfifister D,O'Connor T,et al.The immunology of hepatocellular carcinoma[J].Nat Immunol,2018,19（3）:222-232.
［13］彭米林.HCV与HIV混合感染研究进展［J］.国际病毒学杂志，2010，17（5）：139-142.
［14］中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准［J］.中华肝脏病杂志，2008，8（3）：135-135.
［15］Della Corte C,Triolo M,Iavarone M,et al.Early diagnosis of liver cancer:an appraisal of international recommendations and future perspectives[J].Liver Int,2016,36（2）:166-176.(https://www.daowen.com)
［16］Merchante N,Rodríguez-Fernández M,Pineda JA.Screening for hepatocellular carcinoma in HIV-infected patients:Current evidence and controversies[J].Curr HIV/AIDS Rep,2020,17（1）:6-17.
［17］Zhang X,El-Serag HB,Thrift AP.Predictors of five-year survival among patients with hepatocellular carcinoma in the United States:an analysis of SEER-Medicare[J].Cancer Causes Control,2021,32（4）:317-325.
［18］Singal AG,Zhang E,Narasimman M,et al.HCC surveillance improves early detection,curative treatment receipt,and survival in patients with cirrhosis:A Metaanalysis[J].J Hepatol,2002,77（1）:128-139.
［19］Tzartzeva K,Obi J,Rich NE,et al.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis:A Meta-analysis[J].Gastroenterology,2018,154（6）:1706-1718.
［20］O'Connell J,Rooney S.Screening for hepatocellular carcinoma in chronic liver disease:a systematic review and Meta-analysis of randomized controlled trials comparing screening methodologies[J].J Glob Health Rep,2020,4（6）:e2020041.
［21］Parikh ND,Tayob N,Singal AG.Blood-based biomarkers for hepatocellular carcinoma screening:Approaching the end of the ultrasound era?[J].J Hepatol,2023,78（1）:207-216.
［22］Chang ML,Liaw YF.Hepatitis B flares in chronic hepatitis B:pathogenesis,natural course,and management[J].J Hepatol,2014,61（6）:1407-1417.
［23］Tayob N,Lok AS,Do KA,et al.Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm[J].Clin Gastroenterol Hepatol,2016,14（3）:469-475.
［24］Choi J,Kim GA,Han S,et al.Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma[J].Hepatology,2019,69（5）:1983-1994.
［25］Clark T,Maximin S,Meier J,et al.Hepatocellular carcinoma:Review of epidemiology,screening,imaging diagnosis,response assessment,and treatment[J].Curr Probl Diagn Radiol,2015,44（6）:479-486.
［26］刘彤华.诊断病理学［M］.北京：人民卫生出版社，2019.
［27］Micali C,Russotto Y,Caci G,et al.Venanzi Rullo E.Loco-regional treatments for hepatocellular carcinoma in people living with HIV[J].Infect Dis Rep,2022,14（1）:43-55.
［28］Lim C,Goutte N,Gervais A,et al.Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma[J].J Acquir Immune Defic Syndr,2012,61（5）:581-587.
［29］Feng MY,Chan LL,Chan SL.Drug treatment for advanced hepatocellular carcinoma:First-line and beyond[J].Curr Oncol,2022,29（8）:5489-5507.
［30］陈晹，万来忆，朱益军，等.合并HIV感染肝细胞癌肝切除的回顾性分析—单中心7年数据总结［J］.肝胆胰外科杂志，2022，34（9）：519-525.